Corient Private Wealth LLC Lowers Stake in BioNTech SE (NASDAQ:BNTX)

Corient Private Wealth LLC lessened its holdings in BioNTech SE (NASDAQ:BNTX) by 7.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,784 shares of the company’s stock after selling 150 shares during the quarter. Corient Private Wealth LLC’s holdings in BioNTech were worth $203,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Jones Financial Companies Lllp boosted its position in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. raised its stake in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the last quarter. GAMMA Investing LLC boosted its holdings in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after acquiring an additional 300 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech in the fourth quarter worth $137,000. Finally, AlphaCentric Advisors LLC bought a new position in shares of BioNTech during the fourth quarter valued at $168,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of analyst reports. Wells Fargo & Company began coverage on shares of BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target on the stock. HC Wainwright dropped their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a research note on Tuesday. Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Finally, BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Stock Performance

Shares of BNTX opened at $90.29 on Wednesday. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The business has a fifty day moving average of $110.45 and a 200 day moving average of $113.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market capitalization of $21.67 billion, a P/E ratio of -43.00 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the previous year, the company posted $1.90 EPS. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.